Evidence map›Paper›PMID 36753444›Full record

ArticleAnalytical chemistry2023

Protease-Responsive Potential-Tunable AIEgens for Cell Selective Imaging of TMPRSS2 and Accurate Inhibitor Screening.

Yong Cheng, Alex E Clark, Wonjun Yim, Raina M Borum, Yu-Ci Chang, Zhicheng Jin, Tengyu He, Aaron F Carlin, Jesse V Jokerst

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yong ChengDepartment of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States.
Alex E ClarkDepartment of Medicine, University of California, San Diego, La Jolla, California 92093, United States.
Wonjun YimMaterials Science and Engineering Program, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-0242-7898
Raina M BorumDepartment of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-4265-3109
Yu-Ci ChangMaterials Science and Engineering Program, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0001-6997-9884
Zhicheng JinDepartment of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0001-6072-7533
Tengyu HeMaterials Science and Engineering Program, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-6767-4849
Aaron F CarlinDepartment of Medicine, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-1669-8066
Jesse V JokerstDepartment of NanoEngineering, University of California, San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-2829-6408
University of California San Diego · US

Funding

Validation of Smart Masks for Surveillance of COVID-19R01DE031114 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOKERST, JESSE VINCENT · 2021 to 2023
$1.2M
Deconvolution of pro- and anti-viral responses to Dengue virus and Zika Virus infectionsK08AI130381 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARLIN, AARON F. · 2019 to 2023
$1.0M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
Non-Invasive Detection and Staging of Decubitus and Diabetic UlcersR21AG065776 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOKERST, JESSE VINCENT · 2020 to 2021
$575k
Imaging SARS-CoV-2 proteases for spatio-temporal insight into Covid-19R21AI157957 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOKERST, JESSE VINCENT · 2020 to 2020
$434k
NCI NIH HHS T32 CA153915NIAID NIH HHS K08 AI130381NIAID NIH HHS R21 AI157957NIA NIH HHS R21 AG065776NIDCR NIH HHS R01 DE031114
6 · The paper itself

Abstract

Transmembrane protease serine 2 (TMPRSS2) is a plasma membrane protease that activates both spike protein of coronaviruses for cell entry and oncogenic signaling pathways for tumor progression. TMPRSS2 inhibition can reduce cancer invasion and metastasis and partially prevent the entry of SARS-CoV-2 into host cells. Thus, there is an urgent need for both TMPRSS2-selective imaging and precise screening of TMPRSS2 inhibitors. Here, we report a TMPRSS2-responsive surface-potential-tunable peptide-conjugated probe (EGTP) with aggregation-induced emission (AIE) features for TMPRSS2 selective imaging and accurate inhibitor screening. The amphiphilic EGTP was constructed with tunable surface potential and responsive efficiency with TMPRSS2 and its inhibitor. The rational construction of AIE luminogens (AIEgens) with modular peptides indicated that the cleavage of EGTP led to a gradual aggregation with bright fluorescence in high TMPRSS2-expressing cells. This strategy may have value for selective detection of cancer cells, SARS-CoV-2-target cells, and screening of protease inhibitors.

Indexed as

COVID-19Peptide HydrolasesCell MembraneHumansProtease InhibitorsSARS-CoV-2Serine EndopeptidasesVirus InternalizationPeptide HydrolasesProtease InhibitorsSerine EndopeptidasesTMPRSS2 protein, human

Identifiers

PMID36753444
PMCPMC10614162
OpenAlexW4319461278

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.